Patents by Inventor Jens Fogh
Jens Fogh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10159718Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.Type: GrantFiled: June 9, 2017Date of Patent: December 25, 2018Assignee: Chiesi Farmaceutici S.p.AInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Pia Hydén, Helena Reuterwall, Stefan Nilsson
-
Patent number: 9986722Abstract: The present invention relates to an animal model for infantile globoid cell leucodystrophy, and use of said animal model for screening and/or validation of agents which may be useful as a medicament for treatment of globoid cell leukodystrophy.Type: GrantFiled: August 7, 2013Date of Patent: June 5, 2018Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jens Fogh, Claes Andersson
-
Patent number: 9957489Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: GrantFiled: August 2, 2013Date of Patent: May 1, 2018Assignee: Shire Pharmaceuticals Ireland LimitedInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Publication number: 20180112202Abstract: The present invention relates to a process for purifying recombinant human Galactocerebroside ?-Galactosidase (rhGALC) from a cell culture, wherein a fraction of said cell culture comprising rhGALC is subjected to chromatography on three distinct resins.Type: ApplicationFiled: November 22, 2017Publication date: April 26, 2018Inventors: Jens Fogh, Claes Andersson, Pia Hydén, Pia Ringholm Gulstad, Kerstin Lundell, Magnus Hjertman
-
Publication number: 20180036387Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.Type: ApplicationFiled: June 9, 2017Publication date: February 8, 2018Inventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Pia Hydén, Helena Reuterwall, Stefan Nilsson
-
Publication number: 20150306186Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.Type: ApplicationFiled: March 2, 2015Publication date: October 29, 2015Inventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Pia Hydén, Helena Reuterwall, Stefan Nilsson
-
Publication number: 20150284698Abstract: The present invention relates to a process for purifying recombinant human Galactocerebroside ?-Galactosidase dase (rhGALC) from a cell culture, wherein a fraction of said cell culture comprising rhGALC is subjected to chromatography on three distinct resins.Type: ApplicationFiled: November 13, 2013Publication date: October 8, 2015Inventors: Jens Fogh, Claes Andersson, Pia Hydén, Pia Ringholm Gulstad, Kerstin Lundell, Magnus Hjertman
-
Publication number: 20150196014Abstract: The present invention relates to an animal model for infantile globoid cell leucodystrophy, and use of said animal model for screening and/or validation of agents which may be useful as a medicament for treatment of globoid cell leukodystrophy.Type: ApplicationFiled: August 7, 2013Publication date: July 16, 2015Applicant: Ace Biociences A/SInventors: Jens Fogh, Claes Andersson
-
Patent number: 8974780Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.Type: GrantFiled: February 23, 2011Date of Patent: March 10, 2015Assignee: Zymenex A/SInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Pia Hydén, Helena Reuterwall, Stefan Nilsson
-
Publication number: 20140072548Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: ApplicationFiled: August 2, 2013Publication date: March 13, 2014Applicant: Shire Pharmaceuticals Ireland LimitedInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Patent number: 8536315Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: GrantFiled: January 30, 2005Date of Patent: September 17, 2013Assignee: Shire Pharmaceuticals Ireland LimitedInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Publication number: 20120308549Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.Type: ApplicationFiled: February 23, 2011Publication date: December 6, 2012Applicant: ZYMENEX A/SInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Pia Hydén, Helena Reuterwall, Stefan Nilsson
-
Publication number: 20080003211Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: ApplicationFiled: January 30, 2005Publication date: January 3, 2008Applicant: ZYMENEX A/SInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Patent number: 7148048Abstract: A process for purification of recombinant porphobilinogen deaminase (rhPBGD) on an industrial scale by starting from a rhPBGD containing extract obtained from a fermentation of a recombinant cell capable of expressing the rhPBGD and the use of the purified product for the preparation of a medicament.Type: GrantFiled: December 13, 2002Date of Patent: December 12, 2006Assignee: Zymenex A/SInventors: Jens Fogh, Claes Andersson
-
Publication number: 20030223979Abstract: A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoetic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).Type: ApplicationFiled: March 21, 2003Publication date: December 4, 2003Inventors: Par Gellerfors, Jens Fogh
-
Publication number: 20030199073Abstract: The present invention relates to a cell capable of producing recombinant human LAMAN (rhLAMAN), said cell comprising the 3066 basepair EcoRI-XbaI fragment of a human cDNA which codes for a human LAMAN protein in which the position corresponding to position 186 of the full length hLAMAN protein is Aspartic acid (Asp, D). In particular, the invention relates to a cell comprising a DNA sequence which codes for the amino acid sequence shown in SEQ ID NO 12. One embodiment is an expression plasmid pLamanExp1 having the sequence shown in SEQ ID NO. 2.Type: ApplicationFiled: December 10, 2002Publication date: October 23, 2003Applicant: HemeBiotech A/SInventors: Jens Fogh, Meher Irani, Claes Andersson, Cecilia Weigelt
-
Publication number: 20030180926Abstract: A process for purification of recombinant porphobilinogen deaminase (rhPBGD) on an industrial scale by starting from a rhPBGD containing extract obtained from a fermentation of a recombinant cell capable of expressing the rhPBGD and the use of the purified product for the preparation of a medicament.Type: ApplicationFiled: December 13, 2002Publication date: September 25, 2003Applicant: HemeBiotech A/SInventors: Jens Fogh, Claes Andersson
-
Patent number: 6537777Abstract: A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is an enzyme or an enzymatically equivalent part or analogue thereof. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata prophyria (VP), Congenital erthropoetic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).Type: GrantFiled: July 22, 1999Date of Patent: March 25, 2003Assignee: Hemebiotech A/SInventors: Par Gellerfors, Jens Fogh